^
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-05-07 06:14:45 UTC
Verified By
Rollup News
Novo Nordisk has adjusted its financial outlook due to increased competition in the US market affecting sales of its key obesity and diabetes medications.
Sales forecast reduction
Increased competition in the US
Impact on obesity and diabetes drug sales
Increased competition from other drug manufacturers in the US market
Maintaining sales volume of key drugs in competitive environment